维奈克拉联合酪氨酸激酶抑制剂及减低剂量化疗治疗13例微小残留病阳性及难治复发Ph阳性急性淋巴细胞白血病的疗效与安全性
回顾性分析2015年7月至2024年2月郑州大学附属肿瘤医院13例MRD阳性及R/R Ph(+) ALL患者,采用维奈克拉联合TKI及减低剂量化疗再诱导。10例MRD阳性中9例(90%)达完全分子学缓解,中位达缓解时间47天;3例R/R中2例(66.6%)达完全缓解。全组中位OS及RFS分别为21.5个月和7个月;5例(38.4%)发生≥3级血液学不良反应,造血功能均恢复。
要点
- MRD阳性组9/10例(90%)达完全分子学缓解,中位达缓解时间47天。
- R/R组2/3例(66.6%)达完全缓解,1例无效。
- 5例(38.4%)发生≥3级血液学不良反应,造血功能均恢复,无≥3级感染及脏器不良反应。
核心结论
- 维奈克拉联合TKI及减低剂量化疗治疗MRD阳性及R/R Ph(+) ALL,能够明显提高MRD清除率,获得CMR且治疗相关不良反应可耐受。
研究设计与样本
- 回顾性分析2015年7月至2024年2月郑州大学附属肿瘤医院收治的13例MRD阳性及R/R Ph(+) ALL患者的临床资料。
- 13例中男7例、女6例,中位年龄50岁(范围37~71岁);MRD阳性10例,R/R 3例。
- 再诱导治疗采用以维奈克拉、TKI为基础联合减低剂量化疗。
主要发现
- 10例MRD阳性患者中9例(90%)达完全分子学缓解,中位达到时间为47天(范围30~80天),1例无效。
- 3例R/R患者中2例(66.6%)达完全缓解,1例无效。
- 所有患者中位总生存期及无事件生存期分别为21.5个月及7个月。
- 获得CMR患者中位总生存期及无事件生存期分别为35个月及34个月。
- 5例患者(38.4%)发生3级及以上血液学不良反应,所有患者经治疗后造血功能恢复,无重症感染及3级以上脏器不良反应发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study sought to evaluate the efficacy and safety of venetoclax (Ven) in combination with tyrosine kinase inhibitors (TKI) and reduced-dose chemotherapy for the treatment of patients with minimal residual disease (MRD) -positive and relapsed/refractory (R/R) Ph-positive acute lymphoblastic leukemia (Ph(+) ALL). A retrospective analysis was conducted on the clinical data of 13 patients with MRD-positive and relapsed Ph(+) ALL admitted between July 2015 and February 2024 at the Affiliated Cancer Hospital of Zhengzhou University. The cohort included seven males and six females, with a median age of 50 years (range: 37-71 years). Reinduction therapy consisted of Ven and TKI administration combined with reduced-dose chemotherapy. Among the 13 patients, 10 were MRD-positive, and three had R/R disease. Of the MRD-positive group, nine (90%) achieved complete molecular response (CMR), with a median time to response of 47 days (range: 30-80) ; one patient did not respond. Among the three patients who had R/R, two (66.6%) achieved complete remission, while one patient was nonresponsive. The median overall survival (OS) and relapse-free survival (RFS) time for the entire cohort were 21.5 months and 7 months, respectively. In patients who achieved CMR, the median OS and RFS time were 35 months and 34 months, respectively. Grade ≥3 hematologic adverse events occurred in five patients (38.4%) ; however, hematopoietic function recovered in all cases, and no grade ≥3 infections or organ-related adverse reactions were observed. These findings suggest that Ven combined with TKI and reduced-dose chemotherapy may be an effective and tolerable therapeutic strategy for MRD-positive and R/R Ph(+) ALL, particularly in significantly improving MRD clearance rates. 为探讨维奈克拉(Venetoclax,Ven)联合酪氨酸激酶抑制剂(TKI)及减低剂量化疗治疗微小残留病(MRD)阳性及难治复发(R/R)Ph阳性急性淋巴细胞白血病(Ph(+) ALL)患者的疗效及安全性,回顾性分析2015年7月至2024年2月郑州大学附属肿瘤医院收治的13例MRD阳性及R/R Ph(+) ALL临床资料,男7例,女6例,中位年龄50(37~71)岁,再诱导治疗采用以Ven、TKI为基础联合减低剂量化疗。13例患者中,MRD阳性10例,R/R 3例。10例MRD阳性患者,9例达分子学缓解(CMR),中位达到时间为47(30~80)d,1例无效;3例R/R患者,2例达完全缓解(CR),1例无效。所有患者中位总生存(OS)及无事件生存(EFS)期分别为21.5个月及7个月;获得CMR患者中位OS及EFS期分别为35个月及34个月。5例患者发生了3级及以上血液学不良反应,所有患者经治疗后造血功能恢复,同时无重症感染及3级以上脏器不良反应发生。提示Ven联合TKI及减低剂量化疗治疗MRD阳性及R/R Ph(+) ALL,能够明显提高MRD清除率,获得CMR且治疗相关不良反应可耐受。.
引用
- Ai H, Liang TT, Wang Q, et al. [Efficacy and safety of venetoclax combined with tyrosine kinase inhibitors and reduced-dose chemotherapy in 13 cases of minimal residual disease-positive and relapsed/refractory Ph(+) acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40887423. doi:10.3760/cma.j.cn121090-20241202-00521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。